OncoSec Medical Inc (ONCSQ)

[chickpea598]

Robert Andtbacka, MD, is a clinical and scientific advisor to Oncosec. Just a reminder to investors here that Dr. Andtbacka is recognized as a leader in intratumoral immunotherapies, and he was pivotal in the approval of Amgen’s oncolytica virus therapy, T-VEC, for melanoma. Amgen forked up 1 Billion dollars for t-vec therapy. There may be many ifs regarding whether or not Oncosec results will hold up to a larger sized trial like the one t-vec did which enrolled over 400 patients. IF the results from our combo trial with Keytruda lead to a larger registration trial that are equal to or better than the t-vec results then a 1 Billion dollar buyout is not a far-fetched outcome at some point......just something to think about. Reading a little bit about Robert Andtbacka leads me to believe he is motivated to bring melanoma therapies up to speed with other cancers.